Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

RPL-554 in combination with MRP4 blocker as potential adjunct therapy for CF

Oct. 28, 2014

SHIELD 4 phase III data presented for vercirnon in patients with Crohn's disease

Oct. 27, 2014

First-in-human results presented for radiolabeled antibody [68Ga]ABY-025

Oct. 27, 2014

Phase III data from GEMINI trials presented for vedolizumab

Oct. 27, 2014

Serum bilirubin: a prognostic marker in primary sclerosing cholangitis

Oct. 27, 2014

Kinetic analysis of the new PET ligand [11C]Lu-AE-92686

Oct. 27, 2014

Phase II MenABCWY vaccine results disclosed

Oct. 24, 2014

CCX-507 demonstrates safety and efficacy in phase I trials

Oct. 24, 2014

Vertex presents KONDUCT trial results of ivacaftor in patients with CFTR R117H mutations

Oct. 24, 2014

First-in-human results for oral gut-targeted anti-TNF antibody in acute ulcerative colitis

Oct. 24, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...